Annovis Bio, Inc.
ANVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.03 | -0.07 | -0.08 |
| FCF Yield | -35,731.44% | -23.69% | -15.79% | -6.81% |
| EV / EBITDA | -2.23 | -3.62 | -3.21 | -6.10 |
| Quality | ||||
| ROIC | -265.76% | -759.55% | -90.07% | -32.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.71 | 0.68 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -54,681.29% | -130.85% | -89.58% | -129.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 0.13 | 1.12 | 3.15 |
| Interest Coverage | -14.40 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |